Microbio

Our CSO, Flavia Huygens will be presenting at the 50th Redefining Early Stage Investments (RESI) Conference on January 14 at the San Francisco Marriott Marquis. RESI JPM a platform connecting early-stage life sciences investors, innovators, and industry experts. Held alongside the J.P. Morgan Healthcare Week, #RESIJPM will offer the opportunity to learn about Microbio’s cutting-edge diagnostic solutions and network with global leaders in healthcare investment. Don’t miss this chance to learn about our work in sepsis-related pathogen identification and connect with us! Send a meeting request here: https://hubs.li/Q030x4QX0. See you in San Francisco! 🌍 Life Science Nation #LifeSciences #RESIJPM #HealthcareInvestment #Sepsis #InfectID #Microbio

As the holiday season approaches, we want to take a moment to thank all our partners and colleagues for a year filled with innovation, collaboration, and progress. At Microbio, we remain committed to advancing pathogen detection solutions that make a difference in patient care. This holiday season, we’re reflecting on the impact we’ve made together and looking forward to a bright and impactful year ahead. From our team to yours, we wish you a happy holiday season and a healthy, prosperous New Year! 🌟 #HappyHolidays #SeasonGreetings #Microbio #PathogenDetection

Microbio has partnered with AdviSains - Biotechnology Solutions to bring InfectID™-BSI to healthcare providers in Indonesia! 🇮🇩 This advanced molecular diagnostic test identifies 26 sepsis-associated pathogens directly from blood samples in less than 3 hours without the need for enrichment or culture. By enabling faster and more precise pathogen detection, InfectID™-BSI supports clinicians in delivering targeted treatment and improving patient outcomes. With Advisains’ market expertise, this collaboration opens new doors for enhancing sepsis care across Indonesia, addressing a critical global health challenge. #SepsisCare #HealthcareInnovation #PathogenDetection #Diagnostics #Indonesia

Welcome Larrisa C. to the Microbio team! Larrisa is a final-year BSc student at the University of Queensland, and she has recently joined Microbio as a Junior Laboratory Scientist. With a strong foundation in Biochemistry and Molecular Biology, she brings valuable experience in market research, organic synthesis, and laboratory analytics. Larrisa is eager to contribute to Microbio's mission to combat the global sepsis issue. We're thrilled to have her on board!

We are pleased to announce the launch of our newly redesigned website, featuring an updated look that reflects our evolving brand and commitment to innovation in sepsis-related pathogen identification. Our new site offers streamlined navigation, enhanced functionality, and comprehensive information about our InfectID™-BSI solution, making it easier than ever to understand how we’re advancing pathogen identification for better patient outcomes. Visit us at https://hubs.li/Q02_KsGv0 to explore our updated branding and learn more about our mission. #Microbio #NewWebsite #PathogenIdentification #Sepsis

Microbio was proud to participate in the Access Industry: Building PhD Connections event hosted by the Faculty of Science at the University of Queensland. This engaging evening brought together PhD students and industry representatives to foster meaningful connections and explore pathways into impactful careers beyond academia. Our team shared their insights and experiences with aspiring researchers. We’re always thrilled to connect with emerging talent and support the next generation of scientists. 📸 Check out some highlights from the night below! #Networking #TalentToIndustry #Microbio #PhD

We are thrilled to welcome Neil Verdal-Austin to Microbio as our new Chief Operations Officer! Neil brings a wealth of experience, starting with his BCom and GDA from the University of Cape Town (UCT) and qualification as a CA(SA). His career journey began at Orthomedics in Cape Town, where he rose from Financial Manager to CFO and equity partner. In 2006, Neil moved to Sydney, joining SomnoMed, an obstructive sleep apnea company. Over 15 years, he was instrumental in globalizing the business, growing its reach from 3 countries to 28—a remarkable achievement showcasing his operational and strategic expertise. Neil is passionate about gender equality and embraces life’s joys, including time at the beach and travel but still misses the beauty of the African bush. We're excited to have Neil’s leadership and vision driving operational excellence at Microbio! #WelcomeToTheTeam #Leadership #OperationsExcellence #Microbio #NewHire #GlobalExperience #Teamwork #Innovation

Recently, our Microbio team, Field Application Scientist Judith Lucke and Medical Science Liaison Katie Shepherd joined our Portuguese distributor Iberlab - soluções para laboratórios, lda and their customer, Dr. Sandra Rebelo at Centro Hospitalar Universitário de São João. Together with Dr Rebelo’s fantastic team, they supported the hospital's first run of the InfectID™-BSI assay. The team identified pathogens in three sepsis patients, providing potentially life-saving insights for their ongoing care. One of the results was later confirmed by a sputum sample, aligning with the InfectID™-BSI findings—nine days after the assay had delivered its result. The significance of this finding underscores the power of InfectID™-BSI in improving sepsis outcomes. This marks the beginning of an exciting collaboration with a team equally committed to advancing patient care through faster, targeted pathogen identification allowing to drastically speed up targeted treatment. Dr. Sandra Rebelo shared, "Big things start small, and we expect to give bigger steps towards a solution that would improve the clinical approach for our patients. No man is an island, so teamwork is absolutely precious in addressing clinical issues. All together for the same purpose". #SepsisAwareness #RapidDiagnostics #InfectIDBSI #MicrobioCollaboration João Pedro Carvalho Teixeira

We’re proud to welcome Paul Perreault former CEO of CSL and a global biotech leader, as our new strategic advisor. With over 40 years in healthcare and a track record of driving innovation, Paul’s expertise will be instrumental as we bring InfectID™-BSI to more clinicians worldwide. The InfectID™-BSI diagnostic test delivers actionable intelligence to clinicians, enabling them to deliver targeted antimicrobial treatment – improving patient outcomes and reducing the emergence of antimicrobial resistant organisms. The assay detects 26 pathogens associated with more than 94% of sepsis cases in less than 3 hours. Stay tuned as we continue our mission to redefine sepsis care globally. 🌍 #Sepsis #HealthcareInnovation #PathogenDetection

When the Standard of Care cannot identify fastidious or suppressed pathogens, timely and targeted treatment is delayed. InfectID™-BSI changes that, delivering rapid and reliable pathogen identification in less than three hours. 🔍 Why it matters: - Improves accuracy for patients with prior antimicrobial therapy. - Enhances detection of hard-to-culture pathogens. Learn more about how InfectID™-BSI is addressing these challenges: https://hubs.li/Q02-67hc0 #Diagnostics #Sepsis #InfectiousDiseases #PathogenIdentification